Proefschrift

Ideta, A., Tanaka, G., Takeuchi, T., and Aihara, K. (2008). A mathematical model of intermittent androgen suppression for prostate cancer. Journal of Nonlinear Science , 18(6):593–614. 11, 98 Irwin, K., Renzette, N., Kowalik, T., and Jensen, J. (2016). Antiviral drug resistance as an adaptive process. Virus Evolution , 2(1). 6 Jackson, T. (2004a). A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data. Neoplasia , 6(6):697–704. 11, 98 Jackson, T. (2004b). A mathematical model of prostate tumor growth and androgen- independent relapse. Discrete & Continuous Dynamical Systems-B , 4(1):187–201. 11, 98 Jain, H., Clinton, S., Bhinder, A., and Friedman, A. (2011). Mathematical modeling of prostate cancer progression in response to androgen ablation therapy. Proceedings of the National Academy of Sciences , 108(49):19701–19706. 12, 98 Jemal, A., Ward, E., Johnson, C., et al. (2017). Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. JNCI: Journal of the National Cancer Institute , 109(9). 3, 5, 19, 81 Jia, L. and Coetzee, G. (2005). Androgen receptor–dependent PSA expression in androgen- independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus. Cancer Research , 65(17):8003–8008. 112 Jolly, M., Kulkarni, P., Weninger, K., Orban, J., and Levine, H. (2018). Phenotypic plasticity, bet-hedging, and androgen independence in prostate cancer: Role of non-genetic heterogeneity. Frontiers in Oncology , 8:50. 98 Jørgensen, K., Wassermann, T., Jensen, P., et al. (2013). Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long- term experimental evolution of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy , 57(9):4215–4221. 22 Kam, Y., Das, T., Minton, S., and Gatenby, R. (2014). Evolutionary strategy for systemic therapy of metastatic breast cancer: Balancing response with suppression of resistance. Womens Health , 10. 27, 81 Kam, Y., Das, T., Tian, H., Foroutan, P., Ruiz, E., Martinez, G., Minton, S., Gillies, R., and Gatenby, R. (2015). Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with “ersatzdroges”. International Journal of Cancer , 136(4):E188–E196. 49 Kaplan, D., Yu, S., Taddei, T., Reiss, K., Mehta, R., D’Addeo, K., Aytaman, A., Hunt, K., Fox, R., Baytarian, M., et al. (2017). Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost. Journal of Clinical Oncology , 35(4 suppl):385–385. 97 176